MA30427B1 - Derives bicycliques utilises comme inhibiteurs de cetp - Google Patents

Derives bicycliques utilises comme inhibiteurs de cetp

Info

Publication number
MA30427B1
MA30427B1 MA31408A MA31408A MA30427B1 MA 30427 B1 MA30427 B1 MA 30427B1 MA 31408 A MA31408 A MA 31408A MA 31408 A MA31408 A MA 31408A MA 30427 B1 MA30427 B1 MA 30427B1
Authority
MA
Morocco
Prior art keywords
derivatives used
cetp inhibitors
bicyclic derivatives
cetp
bicyclic
Prior art date
Application number
MA31408A
Other languages
English (en)
Inventor
Masashi Kishida
Naoko Matsuura
Hidetomo Imase
Yuki Iwaki
Ichiro Umemura
Osamu Ohmori
Eiji Kawahara
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0609268.8A external-priority patent/GB0609268D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA30427B1 publication Critical patent/MA30427B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DE NOUVEAUX COMPOSÉS DE FORMULE (I), OU UNE COMPOSITION PHARMACEUTIQUE DESDITS COMPOSÉS, TOUTES LES VARIABLES ÉTANT DÉFINIES DANS LE TEXTE. ELLE CONCERNE ÉGALEMENT L'UTILISATION DE CES COMPOSÉS AUX FINS DE TRAITER OU DE RETARDER L'ÉVOLUTION DE MALADIES APPARENTES DANS LESQUELLES CETP EST IMPLIQUÉE.
MA31408A 2006-05-10 2008-11-24 Derives bicycliques utilises comme inhibiteurs de cetp MA30427B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0609268.8A GB0609268D0 (en) 2006-05-10 2006-05-10 Organic compounds
US86648006P 2006-11-20 2006-11-20
US89614207P 2007-03-21 2007-03-21

Publications (1)

Publication Number Publication Date
MA30427B1 true MA30427B1 (fr) 2009-05-04

Family

ID=38445602

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31408A MA30427B1 (fr) 2006-05-10 2008-11-24 Derives bicycliques utilises comme inhibiteurs de cetp

Country Status (17)

Country Link
US (2) US8232403B2 (fr)
EP (1) EP2024356A1 (fr)
KR (1) KR101172120B1 (fr)
AR (1) AR060873A1 (fr)
AU (1) AU2007247385B2 (fr)
CA (1) CA2650954C (fr)
CL (1) CL2007001325A1 (fr)
CR (1) CR10420A (fr)
EC (1) ECSP088891A (fr)
GT (1) GT200800242A (fr)
IL (1) IL195010A0 (fr)
MA (1) MA30427B1 (fr)
MX (1) MX2008014284A (fr)
NO (1) NO20084912L (fr)
TN (1) TNSN08444A1 (fr)
TW (1) TW200813009A (fr)
WO (1) WO2007128568A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
WO2006073973A2 (fr) * 2004-12-31 2006-07-13 Reddy Us Therapeutics, Inc. Nouveaux dérivés de benzylamine en tant qu'inhibiteurs de cetp
JP2009522224A (ja) * 2005-12-29 2009-06-11 ノバルティス アクチエンゲゼルシャフト コレステリルエステル輸送タンパク質（ｃｅｔｐ）の阻害剤としてのピリジニルアミン誘導体
WO2007128568A1 (fr) * 2006-05-10 2007-11-15 Novartis Ag Dérivés bicycliques utilisés comme inhibiteurs de cetp
RU2008148600A (ru) * 2006-05-11 2010-06-20 Новартис АГ (CH) Производные бензиламина в качестве ингибиторов сетр
US7750019B2 (en) 2006-08-11 2010-07-06 Kowa Company, Ltd. Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same
US7790737B2 (en) 2007-03-13 2010-09-07 Kowa Company, Ltd. Substituted pyrimidine compounds and their utility as CETP inhibitors
JP5244095B2 (ja) * 2007-04-13 2013-07-24 興和株式会社 新規なジベンジルアミン構造を有するピリミジン化合物及びこれを含有する医薬
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
US8841478B2 (en) 2008-11-28 2014-09-23 Kowa Company, Ltd. Method for preparing trans-{4-[(alkylamino) methyl]- cyclohexyl}acetic acid ester
PH12012500382A1 (en) * 2009-09-03 2012-10-22 Bioenergenix Heterocyclic compounds for the inhibition of pask
WO2011157827A1 (fr) 2010-06-18 2011-12-22 Sanofi Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683705B1 (fr) 2011-03-08 2015-04-22 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
EP2683699B1 (fr) 2011-03-08 2015-06-24 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120052A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
ES2683350T3 (es) * 2011-07-08 2018-09-26 Novartis Ag Método para tratar la aterosclerosis en sujetos con alto nivel de triglicéridos
US9199967B2 (en) 2011-08-18 2015-12-01 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors
MX352074B (es) 2011-09-27 2017-11-08 Dr Reddys Laboratories Ltd Derivados de 5-bencilaminometil-6-aminopirazolo [3,4-b] piridina como inhibidores de proteina de transferencia de ester de colesterilo (cetp) utiles para el tratamiento de aterosclerosis.
US20170071930A1 (en) * 2012-11-19 2017-03-16 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of cetp inhibitors
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
US20160000799A1 (en) * 2013-02-21 2016-01-07 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of cetp inhibitors
CN105705167A (zh) 2013-07-25 2016-06-22 诺华股份有限公司 合成的apelin多肽的生物缀合物
MX2016001020A (es) 2013-07-25 2016-08-03 Novartis Ag Polipeptidos ciclicos para el tratamiento de insuficiencia cardiaca.
CR20170338A (es) 2015-01-23 2017-09-12 Novartis Ag Conjugados de ácidos grasos y apelina sintética con mayor vida media
US12162863B2 (en) 2018-06-12 2024-12-10 Ryvu Therapeutics S.A. Modulators of stimulator of interferon genes (STING)
WO2020249773A1 (fr) 2019-06-12 2020-12-17 Ryvu Therapeutics S.A. Modulateurs de sting (stimulateur de gènes d'interféron) de prochaine génération
JP7426486B2 (ja) * 2019-12-11 2024-02-01 ライブ・セラピューティクス・スプウカ・アクツィーナ インターフェロン遺伝子刺激因子（ｓｔｉｎｇ）のモジュレーターとしての複素環式化合物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586433B2 (en) * 1999-09-23 2003-07-01 Pharmacia Corporation Substituted N-heteroaryl-N-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity
MXPA03001186A (es) * 2000-08-07 2004-04-20 Neurogen Corp Compuestos heterociclicos como ligandos del receptor acido gamma aminobutirico (gabaa).
BR0306208A (pt) * 2002-08-30 2004-10-13 Japan Tobacco Inc Compostos de dibenzilamina e seu uso farmacêutico
ATE552253T1 (de) 2002-11-08 2012-04-15 Novartis Int Pharm Ltd 3-substituierte-6-aryl- pyridin derivate als liganden für c5a-rezeptoren
KR100729883B1 (ko) 2003-03-28 2007-06-18 화이자 프로덕츠 인코포레이티드 죽상경화증 및 비만증을 치료하기 위한 ｃｅｔｐ억제제로서의 1,2,4-치환된 1,2,3,4-테트라하이드로- 및1,2-디하이드로-퀴놀린 및1,2,3,4-테트라하이드로-퀴녹살린 유도체
US7371759B2 (en) * 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
CN1942428A (zh) 2004-04-13 2007-04-04 默克公司 Cetp抑制剂
PE20061124A1 (es) 2004-11-23 2006-10-13 Pfizer Prod Inc Compuestos y derivados de dibencil amina
US7668830B2 (en) 2004-11-29 2010-02-23 Nokia Corporation Access rights
WO2006073973A2 (fr) * 2004-12-31 2006-07-13 Reddy Us Therapeutics, Inc. Nouveaux dérivés de benzylamine en tant qu'inhibiteurs de cetp
JP5225688B2 (ja) 2005-01-06 2013-07-03 トムソン ライセンシング デジタル光プロジェクションシステムにおけるレインボーアーチファクトの低減
EP1901057A1 (fr) 2005-07-07 2008-03-19 Sony Corporation Procédé d'acquisition d'informations sur une substance et dispositif de mesure d'informations sur une substance utilisant une lumière évanescente, ainsi que procédé et dispositif de décision concernant une disposition de base
US7573978B2 (en) 2005-07-11 2009-08-11 University Of Florida Research Foundation, Inc. Variable feathering field splitting for intensity modulated fields of large size
JP4981814B2 (ja) * 2005-12-28 2012-07-25 ドクター・レディーズ・ラボラトリーズ・リミテッド 選択的なベンジルアミン誘導体およびコレステロールエステル転写タンパク質抑制剤としてのその有用性
JP2009522224A (ja) * 2005-12-29 2009-06-11 ノバルティス アクチエンゲゼルシャフト コレステリルエステル輸送タンパク質（ｃｅｔｐ）の阻害剤としてのピリジニルアミン誘導体
PE20071025A1 (es) 2006-01-31 2007-10-17 Mitsubishi Tanabe Pharma Corp Compuesto amina trisustituido
WO2007128568A1 (fr) * 2006-05-10 2007-11-15 Novartis Ag Dérivés bicycliques utilisés comme inhibiteurs de cetp
RU2008148600A (ru) * 2006-05-11 2010-06-20 Новартис АГ (CH) Производные бензиламина в качестве ингибиторов сетр
KR20090080523A (ko) * 2006-11-15 2009-07-24 노파르티스 아게 Ｃετρ 억제제로서의 헤테로시클릭 유도체
KR20090078352A (ko) * 2006-11-15 2009-07-17 노파르티스 아게 유기 화합물

Also Published As

Publication number Publication date
KR20090017580A (ko) 2009-02-18
CL2007001325A1 (es) 2008-07-18
KR101172120B1 (ko) 2012-08-10
US8232403B2 (en) 2012-07-31
CA2650954C (fr) 2014-02-11
GT200800242A (es) 2009-04-29
TW200813009A (en) 2008-03-16
AR060873A1 (es) 2008-07-16
AU2007247385A1 (en) 2007-11-15
AU2007247385B2 (en) 2011-07-14
TNSN08444A1 (en) 2010-04-14
NO20084912L (no) 2009-02-03
US20120225874A1 (en) 2012-09-06
EP2024356A1 (fr) 2009-02-18
ECSP088891A (es) 2008-12-30
WO2007128568A1 (fr) 2007-11-15
MX2008014284A (es) 2008-11-18
CR10420A (es) 2009-02-02
IL195010A0 (en) 2009-08-03
US8410275B2 (en) 2013-04-02
CA2650954A1 (fr) 2007-11-15
US20090227580A1 (en) 2009-09-10

Similar Documents

Publication Publication Date Title
MA30427B1 (fr) Derives bicycliques utilises comme inhibiteurs de cetp
MA31683B1 (fr) Composes et procedes pour moduler fxr
MA31586B1 (fr) Dérivés d'alcools alkyliques de 1-phényl-2-pyridinyle en tant qu'inhibiteurs de la phosphodiestérase
EP1784188A4 (fr) Derives de triazole accoles inhibiteurs de la dipeptidyl peptidase-iv utilises dans le traitement ou la prevention du diabete
MA27560A1 (fr) Nouveaux derives de fluorglycoside heterocycliques, produits pharmaceutiques contenant ces composes et leur utilisation
EP1592689A4 (fr) Derives d'acide 3-amino-4-phenylbutanoique utilises comme inhibiteurs de dipeptidyle peptidase pour le traitement ou la prevention du diabete
EP1589969A4 (fr) Derives d'acide 3-amino-4-phenylbutanoique utilises comme inhibiteurs de la dipeptidyl peptidase pour le traitement ou la prevention du diabete
EP1796669A4 (fr) Aminopiperidines utilisees comme inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
BRPI0410711A (pt) novos compostos
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
ATE384061T1 (de) Imidazo- und thiazolopyridine als jak3-kinase- inhibitoren
MA31000B1 (fr) Derives 2-aza-bicyclo[3.1.0]hexane
EA200501504A1 (ru) Лиганды каннабиноидных рецепторов и их применение
EA200601007A1 (ru) 7-фенилалкилзамещённые 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза)полимеразы
EP1888066A4 (fr) Aminocyclohexanes en tant qu'inhibiteurs de dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete
MA29535B1 (fr) Derives d'isoquinoline utilises en tant qu'inhibiteurs de rhokinase
MA30911B1 (fr) Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine
EP1921917A4 (fr) Aminopiperidines fusionnees utilisees comme inhibiteurs de dipeptidyl-peptidase-iv pour le traitement ou la prevention du diabete
MA27556A1 (fr) Derives de phenylalanine comme inhibiteurs de la dipeptidyl peptidase pour le traitement ou la prevention du diabete
TNSN08038A1 (en) Cyclohexylamin isoquinolone derivatives as rho-kinase inhibitors
MA31021B1 (fr) Derives de l'isoquinoleine et de l'isoquinoleinone substituees en tant qu'inhibiteurs de la rho-kinase
UA93882C2 (ru) Пиперидинил-замещенные производные изохинолона kak ингибиторы rho-киназы
EP2091328A4 (fr) Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer
DE60214990D1 (de) Benzolsulfonsäureester-indol-5-yl als 5-ht6 rezeptor-antagonisten